Lineage Cell Therapeutics (LCTX) Gross Profit (2011 - 2026)

Lineage Cell Therapeutics' Gross Profit history runs 16 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Gross Profit rose 17.67% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 57.99% YoY), while the FY2025 annual figure was $14.4 million, up 57.23% from the prior year.
• Gross Profit for Q1 2026 stood at $1.7 million, down from $6.5 million in the prior quarter.
• The five-year high for Gross Profit was $6.5 million in Q4 2025, with the low at $1.1 million in Q3 2023.
• The 5-year median for Gross Profit is $2.7 million (2024), against an average of $2.8 million.
• The sharpest annual moves came in 2022 and 2023: Gross Profit surged 1713.98% in 2022, then plunged 61.02% in 2023.
• Lineage Cell Therapeutics' Gross Profit stood at $1.8 million in 2022, then gained by 1.05% to $1.8 million in 2023, then jumped by 48.14% to $2.7 million in 2024, then jumped by 141.05% to $6.5 million in 2025, then plunged by 73.63% to $1.7 million in 2026.
• Business Quant data shows LCTX's Gross Profit at $1.7 million in Q1 2026, $6.5 million in Q4 2025, and $3.7 million in Q3 2025.